Nexentis Technologies Inc. (NXTS) stock
NXTSNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.99−0.22 (-9.95%)
Close on Nov 16, 2026Market cap $2.89MP/E –Yield –
Nexentis Technologies r&d expenses
Research and development expenses are spending on new products and technology.
Nexentis Technologies's R&D Expenses for the twelve months ending Jun 30, 2026 was $798.00K, up 110.6% year over year. For fiscal 2025 it was $179.00K, down 51.5% from the year before. The highest annual figure on record is $1.94M in fiscal 2023.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $179.00K | -51.5% |
| FY2024 | Dec 31, 2024 | $369.00K | -81.0% |
| FY2023 | Dec 31, 2023 | $1.94M | +151.4% |
| FY2022 | Dec 31, 2022 | $770.83K | +43.1% |
| FY2021 | Dec 31, 2021 | $538.68K | +29.2% |
| FY2020 | Dec 31, 2020 | $417.00K | -32.3% |
| FY2019 | Dec 31, 2019 | $615.62K | +72.4% |
| FY2018 | Dec 31, 2018 | $357.08K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $373.00K | +4044.4% |
| Q1 FY2026 | Mar 31, 2026 | $275.00K | +1275.0% |
| Q4 FY2025 | Dec 31, 2025 | $98.00K | -70.4% |
| Q3 FY2025 | Sep 30, 2025 | $52.00K | +173.7% |
| Q2 FY2025 | Jun 30, 2025 | $9.00K | +50.0% |
| Q1 FY2025 | Mar 31, 2025 | $20.00K | -82.8% |
| Q4 FY2024 | Dec 31, 2024 | $331.00K | +203.6% |
| Q3 FY2024 | Sep 30, 2024 | $19.00K | -98.9% |
| Q2 FY2024 | Jun 30, 2024 | $6.00K | -64.4% |
| Q1 FY2024 | Mar 31, 2024 | $116.00K | -2.4% |
| Q4 FY2023 | Dec 31, 2023 | $109.03K | -56.3% |
| Q3 FY2023 | Sep 30, 2023 | $1.69M | +753.0% |
| Q2 FY2023 | Jun 30, 2023 | $16.86K | -85.1% |
| Q1 FY2023 | Mar 31, 2023 | $118.91K | -43.2% |
| Q4 FY2022 | Dec 31, 2022 | $249.59K | +42.1% |
| Q3 FY2022 | Sep 30, 2022 | $198.50K | +198.6% |
| Q2 FY2022 | Jun 30, 2022 | $113.38K | -50.0% |
| Q1 FY2022 | Mar 31, 2022 | $209.36K | +200.0% |
| Q4 FY2021 | Dec 31, 2021 | $175.68K | +130.6% |
| Q3 FY2021 | Sep 30, 2021 | $66.47K | -24.0% |
| Q2 FY2021 | Jun 30, 2021 | $226.74K | +136.9% |
| Q1 FY2021 | Mar 31, 2021 | $69.79K | -55.7% |
| Q4 FY2020 | Dec 31, 2020 | $76.19K | -68.8% |
| Q3 FY2020 | Sep 30, 2020 | $87.47K | -42.6% |
| Q2 FY2020 | Jun 30, 2020 | $95.71K | +9.8% |
| Q1 FY2020 | Mar 31, 2020 | $157.64K | +19.6% |
| Q4 FY2019 | Dec 31, 2019 | $244.22K | – |
| Q3 FY2019 | Sep 30, 2019 | $152.40K | – |
| Q2 FY2019 | Jun 30, 2019 | $87.18K | – |
| Q1 FY2019 | Mar 31, 2019 | $131.83K | – |
See a number that looks wrong?